A Randomized, Open-label, Multiple-dose Crossover Phase 1 Clinical Trial to Compare and Evaluate the Safety, Pharmacokinetics and Pharmacodynamics Characteristics After Oral Administration of UI059 and UIC202201 in Healthy Adult Volunteers
Latest Information Update: 06 May 2024
Price :
$35 *
At a glance
- Drugs UI 059 (Primary)
- Indications Gastro-oesophageal reflux
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Korea United Pharm Inc
- 06 May 2024 New trial record